Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 894 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cytosine arabinoside Clear all
Completed Phase 2 Interventional Results available

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02666950
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, WEE1 Inhibitor AZD1775
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

NCT00003217
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
12
States / cities
Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Treatment for Advanced B-Cell Lymphoma

NCT01859819
View directory record Official record
Conditions
Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma
Interventions
Rituximab, IT Cytarabine
Drug
Lead sponsor
New York Medical College
Other
Eligibility
3 Years to 31 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
5
States / cities
Buffalo, New York • Valhalla, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 14, 2026, 10:59 PM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

NCT05157971
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 54 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 1 Interventional

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

NCT00080925
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
filgrastim, graft-versus-tumor induction therapy, rituximab, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, cytarabine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 14, 2026, 10:59 PM EDT
Terminated Phase 3 Interventional Results available

UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide

NCT00574080
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Interim/Maintenance Dexamethasone, Induction/Consolidation Dexamethasone, Induction/Consolidation Cisplatin, Induction/Consolidation Adriamycin, InductionConsolidation Cyclophosphamide, Induction/Consolidation Etoposide, Induction Pegfilgrastim, Transplant 1 Dexamethasone, Transplant 1 Cisplatin, Transplant 1 Adriamycin, Transplant 1 Cyclophosphamide, Transplant 1 Etoposide, Transplant 1 Melphalan, Transplant 1 and 2 Pegfilgrastim, Autologous Peripheral Blood Stem Cell Transplant (ASCT), Transplant 2 Carmustine, Transplant 2 Etoposide, Transplant 2 Cytarabine, Transplant 2 Melphalan, Transplant 2 Dexamethasone, Transplant 1 and 2 Bortezomib, Transplant 1 and 2 Thalidomide
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 1 Interventional

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

NCT01321346
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
Panobinostat, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
8 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 14, 2026, 10:59 PM EDT
Recruiting Phase 1 Interventional

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

NCT05558124
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Vyxeos, Gemtuzumab Ozogamicin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation

NCT00003143
View directory record Official record
Conditions
Lymphoma
Interventions
Amifostine, DHAP
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 14, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional Results available

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS

NCT01607645
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions
decitabine, idarubicin, cytarabine
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

NCT00244946
View directory record Official record
Conditions
Lymphoma
Interventions
therapeutic autologous lymphocytes, carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation (PBSCT)
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
15 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 14, 2026, 10:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

NCT07153796
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Mini-CVD, MTX/ARA-C
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 14, 2026, 10:59 PM EDT
Recruiting Phase 2 Interventional

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

NCT06660368
View directory record Official record
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 3 Interventional

Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia

NCT00186966
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome), Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan, Hematopoietic stem cell transplant, Total body irradiation
Drug · Procedure · Radiation
Lead sponsor
Dutch Childhood Oncology Group
Other
Eligibility
Up to 18 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 14, 2026, 10:59 PM EDT
Active, not recruiting No phase listed Observational

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

NCT04263181
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Peripheral blood draw, Bone marrow aspirate, Buccal swab
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 3 Interventional

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

NCT00005945
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
3,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
116
States / cities
Phoenix, Arizona • Downey, California • Duarte, California + 92 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00002800
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions
filgrastim, lintuzumab, cytarabine, etoposide, idarubicin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

NCT00002502
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, cytarabine, allogeneic bone marrow transplantation
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 3 Interventional

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

NCT00000658
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Allopurinol, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
22
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 14, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional Results available

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

NCT00505921
View directory record Official record
Conditions
Lymphoma
Interventions
Campath-1H, G-CSF, GM-CSF, BCNU, Stem Cell Transplant, Preparative Regimen for Allogenic Stem Cell Transplantation, Cytarabine, Etoposide, Melphalan, Campath, Fludarabine, Cyclophosphamide, Low dose total body irradiation
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 1 Interventional

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

NCT03349281
View directory record Official record
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Julio Barredo, MD
Other
Eligibility
16 Years to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 14, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional Results available

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

NCT02535806
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
Velcade, Methotrexate, Methotrexate / Hydrocortisone / Cytarabine, Dexamethasone, Mitoxantrone, Vincristine, Pegaspargase
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 39 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 1 Interventional

Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00990054
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Duarte, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 14, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers

NCT00015951
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
bevacizumab, cytarabine, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 14, 2026, 10:59 PM EDT